Concurrent @entity900 , continuous infusion XXXX and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma.

@entity1 @entity137 @entity1494 @entity5 @entity4272 @entity294 @entity900 @entity470 @entity1150 @entity1544 @entity1398 @entity3833 @entity1726 @entity850 @entity1909 @entity1487 @entity250
BACKGROUND: To evaluate efficacy and feasibility of chemo-radiotherapy in @entity1 with non-metastatic @entity1544 . METHODS: TNM staged anal squamous-cell @entity5 @entity1 were treated with pelvic radiotherapy concomitant to continuous infusion @entity1487 plus @entity900 for at least 2 cycles. In T3-T4 or any @entity5 or in "slow-responder" cases, 1-2 chemotherapy courses were subsequently administered. Tumour assessment was performed at baseline and 6-8 weeks after radiotherapy to evaluate response. RESULTS: 29 @entity1 were enrolled: 4 males, 25 females; median age 57 years; baseline T1/T2/T3/T4 2/12/7/8; N involvement 17. Median dose pelvic radiotherapy was 59.4 Gy (range: 54-74). In 5 @entity1 2 chemotherapy courses, in 12 @entity1 three and in 12 @entity1 four courses were performed. At first evaluation, 27 CR (93.1%; 95% CI: 78% - 98%) and 2 SD were observed. Main grade (G) 3 toxic events were @entity1398 (8%), @entity294 (8%) and @entity1909 (62%). Most frequent late events G3-G4 occurred in 14 @entity1 : @entity4272 (5), @entity1909 (4), @entity1494 (2), @entity250 (9), lower extremity @entity1150 (2), @entity3833 (1), @entity850 (1) and tenesmus (1). Five @entity1 reported G1 leucopoenia. The rate of colostomy was 14%. After a median follow up of 42 months (range: 4-81), 20 @entity1 are still alive without relapse and 3 died due to @entity1726 . The estimated 7-year DFS was 83.4% (C.I.: 68.3%-98.5%) and the estimated 7-year OS was 85.7% (C.I.: 70% - 100%). The 1-year and the estimated 7-year colostomy-free survivals were 85.9% (C.I.: 73.1% - 98.7%). CONCLUSIONS: Concurrent @entity900 plus @entity1487 and radiotherapy is associated with favourable local control rates and acute @entity137 . Future investigations will be directed towards research into molecular biomarkers related to disease progression and resistance to chemo-radiotherapy and to the evaluation of new cytotoxic agents or targeted drugs, such as anti- @entity470 , concomitant to RT and to determining the role of intensity-modulated radiotherapy.
